Literature DB >> 6179548

Palliative treatment of tardive dyskinesia with combination of amantadine-neuroleptic administration.

R M Allen.   

Abstract

The author presents six cases which suggest a palliative effect of combination amantadine/neuroleptic in tardive dyskinesia. The six patients all met criteria for definite tardive dyskinesia, and did not have coexistent pseudoparkinsonism. Serial addition and subtraction of amantadine with fixed low-dose neuroleptic points to a specific amantadine effect. Previous studies are reviewed and speculation about the mechanism of action of the combination is discussed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6179548

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  6 in total

1.  Rapid response of disabling tardive dyskinesia to amantadine: a case report.

Authors:  Gaurav Jain
Journal:  Prim Care Companion CNS Disord       Date:  2011

2.  Tardive dyskinesia: therapeutic options for an increasingly common disorder.

Authors:  Leslie J Cloud; Deepti Zutshi; Stewart A Factor
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

3.  Effects of dopamine agonists, catecholamine depletors, and cholinergic and GABAergic drugs on acute dyskinesias in squirrel monkeys.

Authors:  R Neale; S Gerhardt; J M Liebman
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

4.  Interaction between chronic amphetamine and neuroleptic treatments on oral behavior in rats.

Authors:  A D Levy; G D Ellison
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

5.  Tardive dyskinesia in patients treated with atypical antipsychotics: case series and brief review of etiologic and treatment considerations.

Authors:  Jungjin Kim; Eric Macmaster; Thomas L Schwartz
Journal:  Drugs Context       Date:  2014-04-09

Review 6.  Amantadine: reappraisal of the timeless diamond-target updates and novel therapeutic potentials.

Authors:  Wojciech Danysz; Andrzej Dekundy; Astrid Scheschonka; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2021-02-23       Impact factor: 3.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.